PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9871382

Early abortion. Update and implications for midwifery practice.

D Narrigan
View original source ↗Export metadata ↓

Abstract

Medical abortion using methotrexate and misoprostol and manual vacuum aspiration are two new methods for pregnancy termination during the first 8 weeks of gestation. Compared to the regimen of mifepristone (RU 486) and misoprostol, both methods offer high rates of complete abortion and acceptability to users. Limitations of the new two-drug regimen compared with mifepristone include a longer time to effect abortion, transient gastrointestinal side effects, and risk of potential teratogenicity from methotrexate's cytotoxicity. Compared to standard surgical abortion, both methods allow women to avoid surgery, are more privately performed, and may be more easily accessible. The safety of first-trimester abortion provided by nurse practitioners and physician assistants has been established. Whether midwives and either new method to their practices depends on several factors. These include obtaining appropriate training, overcoming legal restrictions, and meeting professional and personal challenges inherent in providing early abortion care.

Explore related subjects

Abortifacient AgentsAbortifacient Agents, NonsteroidalAbortifacient Agents, SteroidalAbortion, InducedFemaleHumansMethotrexateMifepristoneMisoprostolNurse MidwivesPregnancyPregnancy Trimester, FirstSuctionUnited StatesVacuumAbortion, Drug InducedAmericasBiologyDelivery Of Health CareDeveloped CountriesDrugsEndocrine SystemFamily PlanningFertility Control, PostconceptionHealthHealth PersonnelLiterature ReviewNorth AmericaNorthern AmericaNurse-midwivesPhysiologyProstaglandinsProstaglandins, SyntheticTreatmentVacuum AspirationJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Narrigan. Early abortion. Update and implications for midwifery practice.. https://doi.org/10.1016/s0091-2182(98)00057-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Mid-trimester induced abortion: a review.

Mid-trimester abortion constitutes 10-15% of all induced abortion. The aim of this article is to provide a review of the current literature of mid-trimester methods of abortion with respect to efficacy, side effects and acceptability. There have been continuing efforts to improve the abortion technology in terms of effectiveness, technical ease of performance, acceptability and reduction of side effects and complications. During the last decade, medical methods for mid-trimester induced abortion have shown a considerable development and have become safe and more accessible. The combination of mifepristone and misoprostol is now an established and highly effective method for termination of pregnancy (TOP). Advantages and disadvantages of medical versus surgical methods are discussed. Randomized studies are lacking, and more studies on pain treatment and the safety of any method used in patients with a previous uterine scar are debated, and data are scarce. Pain management in abortion requires special attention. This review highlights the need for randomized studies to set guidelines for mid-trimester abortion methods in terms of safety and acceptability as well as for better analgesic regimens.

Abortifacient Agents↗
PubMed2006

Silent rupture of unscarred uterus: an unusual presentation at second trimester abortion.

Rupture of unscarred uterus during the second trimester is rare. A case of ruptured uterus in a multiparous woman is presented. To our knowledge, this might be the first reported case in the English literature of uterine rupture during second trimester termination of pregnancy using ethacridine lactate. This case is also rare as uterine rupture is presented with an insidious course rather than acute, thus delaying the diagnosis.

Abortifacient Agents↗